1. Home
  2. AIM
  3. AIM News

Latest AIM ImmunoTech Inc. (AIM) News on March 25, 2025

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
AIM

GlobeNewswire

14 days ago

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
AIM

GlobeNewswire

25 days ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
AIM

GlobeNewswire

a month ago

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
AIM

GlobeNewswire

a month ago

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
AIM

GlobeNewswire

a month ago

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
AIM

GlobeNewswire

a month ago

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
AIM

GlobeNewswire

a month ago

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
AIM

GlobeNewswire

2 months ago

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks

Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
AIM

GlobeNewswire

2 months ago

Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
AIM

GlobeNewswire

2 months ago

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
AIM

GlobeNewswire

2 months ago

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock?
AIM

Zacks

2 months ago

AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock?

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
AIM

GlobeNewswire

2 months ago

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
AIM

GlobeNewswire

3 months ago

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

AIM

Business Wire

3 months ago

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

AIM

Business Wire

3 months ago

AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy Card

AIM

GlobeNewswire

3 months ago

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

AIM

GlobeNewswire

3 months ago

UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card

AIM

Business Wire

3 months ago

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
AIM

GlobeNewswire

3 months ago

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM

GlobeNewswire

3 months ago

Kellner Group Announces Support from Another Former AIM Senior Executive

AIM

GlobeNewswire

3 months ago

AIM’s Clinical Strategy Under Incumbent Board Has Totally Failed

AIM

Business Wire

3 months ago

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell

AIM

GlobeNewswire

3 months ago

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
AIM

GlobeNewswire

4 months ago

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

AIM

GlobeNewswire

4 months ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

AIM

Business Wire

4 months ago

ISS Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan and Dr. William M. Mitchell

AIM

Business Wire

4 months ago

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board

AIM

GlobeNewswire

4 months ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

AIM ImmunoTech announces cash conservation plan, committment to Ampligen
AIM

TipRanks

4 months ago

AIM ImmunoTech announces cash conservation plan, committment to Ampligen

AIM

Business Wire

4 months ago

AIM ImmunoTech Refutes Activist Group’s False and Misleading Claims

AIM

Business Wire

4 months ago

AIM ImmunoTech Announces Cash Conservation Plan

AIM

GlobeNewswire

4 months ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote Enclosed Gold Card

AIM

Business Wire

4 months ago

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

AIM

PR Newswire

4 months ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
AIM

GlobeNewswire

4 months ago

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

AIM

GlobeNewswire

4 months ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board

AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
AIM

GuruFocus.com

4 months ago

AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
AIM

GlobeNewswire

4 months ago

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
AIM

GlobeNewswire

5 months ago

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
AIM

Business Wire

5 months ago

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM

GlobeNewswire

7 months ago

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
AIM

GlobeNewswire

7 months ago

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
AIM

GlobeNewswire

7 months ago

AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

8 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
AIM

GlobeNewswire

8 months ago

AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

9 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM

GlobeNewswire

9 months ago

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

Better AI Stock: Palantir vs. Snowflake
AIM

Motley Fool

10 months ago

Better AI Stock: Palantir vs. Snowflake

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?
AIM

Motley Fool

10 months ago

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

BigBear.ai Stock: Buy, Sell, or Hold?
AIM

Motley Fool

10 months ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'
AIM

AFP

10 months ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?
AIM

Motley Fool

10 months ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp
AIM

GuruFocus.com

10 months ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...
AIM

GuruFocus.com

10 months ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)
AIM

Simply Wall St.

10 months ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
AIM

GlobeNewswire

10 months ago

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
AIM

GlobeNewswire

10 months ago

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
AIM

GlobeNewswire

10 months ago

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
AIM

GlobeNewswire

10 months ago

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

AIM

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/15/2024

AIM

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/13/2024

AIM

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/10/2024

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
AIM

GlobeNewswire

a year ago

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM

GlobeNewswire

a year ago

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
AIM

GlobeNewswire

a year ago

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
AIM

GlobeNewswire

a year ago

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

AIM ImmunoTech Announces Launch of CEO Corner Platform
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Farmer Brothers to report fiscal second quarter 2024 financial results
AIM

GlobeNewswire

a year ago

Farmer Brothers to report fiscal second quarter 2024 financial results

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

Zacks.com featured highlights Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance
AIM

Zacks

a year ago

Zacks.com featured highlights Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM

Business Wire

a year ago

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied
AIM

PR Newswire

a year ago

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied

H World Group Limited Announces the Change of Officers
AIM

GlobeNewswire

a year ago

H World Group Limited Announces the Change of Officers

AIM

Business Wire

a year ago

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

AIM

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Quarterly Distribution in Stock and Cash

AIM

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Announces Final Results of Rights Offering

AIM

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Announces Preliminary Results of Rights Offering

Share on Social Networks: